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OBJECTIVE—Advanced glycation end products (AGEs) and
the renin-angiotensin system (RAS) are both implicated in the
development of diabetic retinopathy. How these pathways inter-
act to promote retinal vasculopathy is not fully understood.
Glyoxalase-I (GLO-I) is an enzyme critical for the detoxiﬁcation
of AGEs and retinal vascular cell survival. We hypothesized that,
in retina, angiotensin II (Ang II) downregulates GLO-I, which
leads to an increase in methylglyoxal-AGE formation. The angio-
tensin type 1 receptor blocker, candesartan, rectiﬁes this imbal-
ance and protects against retinal vasculopathy.
RESEARCH DESIGN AND METHODS—Cultured bovine ret-
inal endothelial cells (BREC) and bovine retinal pericytes (BRP)
were incubated with Ang II (100 nmol/l) or Ang IIcandesartan
(1 mol/l). Transgenic Ren-2 rats that overexpress the RAS were
randomized to be nondiabetic, diabetic, or diabeticcandesartan
(5 mg/kg/day) and studied over 20 weeks. Comparisons were
made with diabetic Sprague-Dawley rats.
RESULTS—In BREC and BRP, Ang II induced apoptosis and
reduced GLO-I activity and mRNA, with a concomitant increase
in nitric oxide (NO
●), the latter being a known negative regulator
of GLO-I in BRP. In BREC and BRP, candesartan restored GLO-I
and reduced NO
●. Similar events occurred in vivo, with the
elevated RAS of the diabetic Ren-2 rat, but not the diabetic
Sprague-Dawley rat, reducing retinal GLO-I. In diabetic Ren-2
rats, candesartan reduced retinal acellular capillaries, inﬂamma-
tion, and inducible nitric oxide synthase and NO
●, and restored
GLO-I.
CONCLUSIONS—We have identiﬁed a novel mechanism by
which candesartan improves diabetic retinopathy through the
restoration of GLO-I. Diabetes 59:3208–3215, 2010
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hronic hyperglycemia is the major causative
factor in the pathogenesis of diabetic retinopa-
thy (1) and may injure retinal vascular cells
through a number of pathways including the
enhanced production of advanced glycation end products
(AGEs) (2,3) and activation of the renin-angiotensin sys-
tem (RAS) (4). In diabetes, there is an impaired glucose
handling and increased glucose ﬂux through the glycolytic
pathway resulting in the accumulation of the AGE precur-
sor, methylglyoxal (MGO), which is a source of intracel-
lular and plasma AGEs (5). MGO can modify amine groups
(such as lysine and arginine residues) resident on key
cellular proteins, generating AGE-modiﬁed cellular pro-
teins that have negative effects on protein function and
gene regulation (6,7), leading to impaired cell function. In
diabetic retinopathy, MGO-derived AGEs are elevated in
retina and serum and are viewed to be causative in retinal
injury (8,9). The glyoxalase (GLO) system, composed of
GLO-I and GLO-II, is critical for controlling MGO levels in
vivo and, ultimately, MGO-AGEs. However, in diabetes,
GLO-I activity is reduced in some tissues and hence
implicated in the accumulation of tissue MGO and AGEs
and subsequent pathology (10,11). Relevant to diabetic
retinopathy, we reported that, in retinal pericytes grown in
hyperglycemic conditions, when GLO-I function is im-
paired, MGO accumulates and pericyte apoptosis occurs
(12).
The RAS is a major regulator of blood pressure and also
contributes to retinal pathology by stimulating cell death,
inﬂammation, and angiogenesis [reviewed in ref (4)]. The
RAS is initiated by prorenin, and its active form, renin,
liberates angiotensin I from angiotensinogen. Angiotensin
converting enzyme then converts angiotensin I to angio-
tensin II (Ang II). Both experimental and clinical evidence
indicates that Ang II blockade improves aspects of vascu-
lar and neuroglial injury in diabetic retinopathy (13–17).
Indeed, the recent ﬁndings of the DIRECT program (Diabetic
Retinopathy Candesartan Trials) indicate that angiotensin
type 1 receptor blockade (AT1-RB) with candesartan reduces
the incidence of diabetic retinopathy in type 1 diabetic
patients and improves the regression of retinal disease in
type 2 diabetic patients (18,19).
Despite the positive ﬁndings of DIRECT, AT1-RB did not
normalize retinal pathology. This may be due to Ang II’s
interactions with other pathways such as AGEs to induce
organ pathology (20–23). In terms of diabetic retinopathy,
the few studies that have evaluated this relationship have
focused on extracellular events where Ang II increases
AGEs and the receptor for AGEs (RAGE)-induced apopto-
sis of retinal pericytes (24). However, there is little under-
standing about how intracellular AGEs, such as those
generated from MGO through GLO-I inactivation, are
inﬂuenced by the RAS in diabetic retinopathy. In the
present study, we hypothesized that Ang II stimulates the
downregulation of retinal GLO-I with a subsequent in-
crease in MGO formation, leading to increased MGO-AGEs
and vascular damage in diabetic retinopathy. We also
evaluated whether candesartan’s protective effects in dia-
betic retinopathy involves restoration of retinal GLO-I.
Studies were performed in transgenic (mRen-2)27 (Ren-2)
rats, which overexpress the RAS in extrarenal tissues, are
hypertensive and develop accelerated retinopathy com-
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streptozotocin (13,15,25). To more directly evaluate the
relationship between Ang II and GLO-I in retinal vascular
cells, studies were performed in cultured bovine retinal
endothelial cells (BREC) and bovine retinal pericytes
(BRP). Furthermore, given that we have identiﬁed that
nitric oxide (NO
●) is a regulator of GLO-I activity in retinal
pericytes (12), we determined if Ang II’s modulation of
retinal GLO-I is associated with changes in retinal NO
●.
RESEARCH DESIGN AND METHODS
Tissue culture experiments. Culture of BREC and BRP. BREC and BRP
were cultured as previously described (26). Passage numbers were between 3
and 6 for BREC and 3 and 7 for BRP. See the online appendix available at
http://diabetes.diabetesjournals.org/cgi/content/full/db10-0552/DC1 for details
regarding treatment of cells with Ang II and candesartan.
BREC and BRP apoptosis. BRP apoptosis was quantitated by ﬂow cytom-
etry by double staining with annexin-ﬂuorescein isothiocyanate (FITC) and
propidium iodide (TACS AnnexinV-FITC Apoptosis Detection kit, R&D Sys-
tems, Minneapolis, USA) as previously described (12). BREC apoptosis was
not assessed by ﬂow cytometry, as it has been reported that the quantitation
of apoptosis in BREC by this method is unreliable (27). BREC apoptosis was
conducted in 96-well plates and detected by transferase-mediated dUTP
nick-end labeling (TUNEL) staining using an In Situ Cell Death Detection kit
(Roche Diagnostics, NSW, Australia) according to the manufacturer’s instruc-
tions. Cells were counterstained with 300 nmol/l DAPI for 1 min to visualize
the nucleus. Three nonoverlapping ﬁelds/well were captured using a Nikon
Eclipse TE2000-U microscope coupled to a Digital Sight camera (Nikon,
Melville, NY, USA) and interfaced with a computer running NIS Elements
F2.20 (Nikon).
GLO-I activity and expression in BREC and BRP. To determine whether
Ang II inﬂuences GLO-I activity, cell lysates were prepared as previously
described and 10 g of lysate was assayed (12). To measure mRNA levels, 0.5
g of total RNA from either BREC or BRP was extracted using Trizol
(Invitrogen, Vic, Australia) and was DNase treated and reverse transcribed
(26). Real-time PCR was conducted to detect mRNA levels of GLO-I using
SYBR Green UDG Mater Mix (Invitrogen) and an ABI 7900HT Sequence
Detection System (Applied Biosystems, Vic, Australia). Primers are detailed in
the online appendix (Table S1).
NO
● assay in BREC and BRP. Cells were harvested and treated with nitrate
reductase to reduce nitrates to nitrite as previously described (12). NO
● was
quantitated in cells using 2,3-diaminonaphthalene (28). See online appendix
for further detail.
Animal studies. Procedures complied with the National Health and Medical
Research Council of Australia’s (NHMRC) Code of the Care and Use of
Animals for Scientiﬁc Purposes and were approved by the Alfred Medical
Research and Education Precinct’s (AMREP) Animal Ethics Committee.
Female 8-week-old Ren-2 rats were obtained from AMREP Animal Services
Pty. Ltd. Female 8-week-old Sprague-Dawley rats were obtained from the
Animal Research Centre (Perth, WA, Australia) and served as age-matched
controls for Ren-2 rat studies. All rats had free access to normal rat chow and
drinking water. They were housed in a stable environment maintained at 22 
1°C (12 h light–dark cycle). Ren-2 rats were randomized to the following
groups: 1) nondiabetic control, 2) diabetic control, and 3) diabetic
candesartan (5 mg/kg/day, gavage). To make them diabetic, rats were fasted
overnight and given a single tail vein injection of streptozotocin (50 mg/kg,
0.1M citrate buffer; Sigma-Aldrich) (13,15,25). Two to three days later, rats
began treatment with candesartan for 4 or 20 weeks. Diabetic rats received
insulin (Humulin, Eli Lilly Co., USA, 2 units) every 2 days by subcutaneous
injection. Body weight was measured each month. Systolic blood pressure
was measured each month using a tail cuff method (AD Instruments, CO
Springs, CO, USA) (13,15,25). Blood glucose was determined using Accu-
check Advantage II Glucose Meter (Roche, Grenzacherstrasse, Basel, Switzer-
land). Prior to tissue collection, rats were anesthetized with Nembutal (60
mg/kg, Sigma-Aldrich).
Retinal pathology. Acellular capillaries and leukocyte adherence in large
retinal vessels were measured as previously described (13,26). See the online
appendix for further detail.
Real-time PCR in retina. Retinal mRNA levels were determined by real-time
PCR as previously described (26). One g of total RNA extracted from retina
was DNase-treated and reverse transcribed. mRNA levels of vascular endo-
thelial growth factor (VEGF), intercellular adhesion molecule-1 (ICAM-I),
tumor necrosis factor- (TNF-), GLO-I, and inducible nitric oxide synthase
(iNOS) were measured. See online appendix for descriptions of primers
(Table S1).
Retinal GLO-I activity, tissue and plasma MGO-AGE, argpyrimidine
and NO
● levels. For GLO-I activity, ﬂash-frozen whole retina was prepared as
described in the online appendix and 10 g of retina was assayed as described
for BREC and BRP. Tissue MGO-AGE and argpyrimidine, a speciﬁc MGO-
AGE, were detected in undialyzed retinal lysates generated for the GLO-I
assay by direct ELISA. See online appendix for further detail. Plasma
MGO-AGEs and total AGEs (all AGEs including MGO-AGEs) were quantitated
by competitive ELISA. See online appendix for further detail. NO
● was
measured in retinal lysates as described in ref (28). See online appendix for
further detail.
Statistics. For all cell culture studies, experiments were performed in
triplicate and then the entire experiment was independently repeated at least
three times. Data were analyzed using either SPSS v11 (SPSS Inc., Chicago, IL,
USA) or GraphPad Prism ﬁve (GraphPad Software Inc, LA Jolla, CA, USA).
For animal experiments, at least six rats were required in each group to
achieve statistical signiﬁcance. To determine how many animals per group
were required, we compared previous experimental data in diabetic animals
with treated groups for each respective end point and then calculated the
number of animals required to achieve an expected power of 0.8 (80%) and a
P value of 0.05. Both animal and cell culture datasets were assessed for
normality, and in the case of 2 treatments, either one-way ANOVA (para-
metric), followed by appropriate post hoc analyses correcting for the number
of comparisons, or Kruskal-Wallis, followed by individual Mann-Whitney U
tests (nonparametric), was conducted. When only two treatments were given,
either an unpaired t test (parametric) or a Mann-Whitney U test (nonparamet-
ric) was conducted. Investigators were masked to the groups. A value of P 
0.05 was considered signiﬁcant.
RESULTS
Ang II stimulates apoptosis and decreases GLO-I in
BRECs and BRPs. To determine whether Ang II induces
apoptosis in retinal vascular cells, BREC and BRP were
incubated with 100 nmol/l Ang II for 24 h. In BREC and
BRP, Ang II treatment resulted in a 500 and 30% increase
in either TUNEL or Annexin-positive cells, respectively,
compared with control (Fig. 1). Given this ﬁnding, we next
evaluated GLO-I in BREC and BRP and found that, in both
cell types, Ang II decreased GLO-I activity and mRNA by
20% compared with controls (Fig. 2). To conﬁrm the
involvement of Ang II in the downregulation of GLO-I, we
next measured GLO-I after treatment with the AT1-RB,
candesartan. In both BREC and BRP, candesartan restored
both GLO-I activity and mRNA to control levels in Ang
II-treated cells (Fig. 2), and in the case of BREC, GLO-I
mRNA was elevated above control levels (Fig. 2). Overall,
BREC was more responsive to the actions of candesartan
in terms of restoration of GLO-I function. Candesartan in
the absence of Ang II, in almost all instances, did not
inﬂuence GLO-I levels (see supplementary Fig. 1, available
in the online appendix).
Ang II’s reduction of GLO-I and in BRP is accompa-
nied by an increase in NO
●. To determine whether Ang
II’s downregulation of GLO-I involves NO
●, we measured
NO
● production in BREC and BRP after Ang II treatment in
the presence or absence of candesartan. In BREC, Ang II
had no effect on NO
● levels, whereas in BRP, Ang II
increased NO
● production 1.2-fold. In both cell types,
candesartan reduced NO
● levels in Ang II-treated cells
compared with those only receiving Ang II (Fig. 3).
Diabetic Ren-2 rats develop acellular capillaries and
increased retinal leukostasis, which is reduced with
candesartan. The in vivo counterpart of BREC and BRP
apoptosis is the formation of acellular capillaries. To
determine whether GLO-I expression is reduced in retina
from diabetic Ren-2 rats and correlates with acellular
capillary formation, we ﬁrst evaluated the number of
acellular capillaries in retina of Ren-2 rats after 20 weeks
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the mid and peripheral retina of diabetic Ren-2 rats
compared with nondiabetic controls and reduced with
candesartan (Fig. 4). Because leukocyte adherence in
retinal vessels may precede the development of acellular
capillaries, both 4- and 20-week time points were exam-
ined. In diabetic Ren-2 rats, adherent leukocytes were
increased after 4 and 20 weeks of diabetes compared with
nondiabetic controls (Fig. 5), with leukocyte adherence
most pronounced in the 4-week diabetic group. In diabetic
Ren-2 rats, candesartan reduced the increase in leukocyte
adherence in retinal vessels to control levels or below
(Fig. 5).
Gene expression of VEGF, inﬂammatory factors, and
iNOS in retina of diabetic Ren-2 rats. In diabetic Ren-2
rats, the level of retinal ICAM-1 and TNF- mRNA doubled,
and VEGF mRNA increased by 0.5-fold compared with
nondiabetic controls. In diabetic Ren-2 rats, both ICAM-1
and VEGF mRNA levels in retina were reduced with
candesartan to the level of nondiabetic controls (Fig. 6)
and TNF- mRNA was reduced to below nondiabetic
control levels. (Fig. 6). In diabetic Ren-2 rats, the level of
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FIG. 1. BREC and BRP apoptosis as detected by TUNEL staining and
ﬂow cytometry, respectively, after treatment with Ang II. In BREC,
TUNEL staining is increased after treatment with 100 nmol/l Ang II for
2 4h( A) compared with control (C). DAPI nuclear staining of Ang
II-treated (B) and control (D) BREC. Arrows denote TUNEL-positive
BREC, and arrowhead denotes cellular blebbing, a common feature of
apoptosis. Magniﬁcation 200. Representative example of Annexin
V-FITC (x-axis) and propidium iodide (PI) staining (y-axis) to detect
apoptotic cells after treatment of BRP with 100 nmol/l Ang II (E)o r
control (F) for 24 h. Increases were observed in the Annexin V
positive, or early apoptotic phase (bottom right-hand quadrant), and
Annexin V positive/PI positive (top right-hand quadrant), or late
apoptotic phase (E). Bottom left quadrant, viable cells; Top left
quadrant, necrotic cells (PI staining only). G: Graphical representation
of BREC apoptosis detected by TUNEL staining; *P < 0.01 versus
control. N  3 samples and is a representative dataset of three
independent experiments. H: Graphical representation of BRP apopto-
sis detected by Annexin/PI staining; *P < 0.03 versus control. All data
were analyzed by unpaired t tests. N  3 independent experiments.
Values are mean  SEM. (A high-quality color representation of this
ﬁgure is available in the online issue.)
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FIG. 2. GLO-I mRNA and activity levels in BREC and BRP after
treatment with Ang II and candesartan (Cand). In BREC (A and B) and
BRP (C and D), GLO-I mRNA (A and C) and activity (B and D)i s
decreased after treatment with Ang II (100 nmol/l) for 24 h compared
with control. Cand (1 mol/l) restored GLO-I activity and mRNA in
BREC and BRP co-incubated with Ang II. A, B:* P < 0.05 versus control,
†P < 0.05 versus Ang II. C and D:* P < 0.03 versus control. All data
were analyzed by Kruskal-Wallis test, followed by Mann-Whitney U
tests. Values are the mean of N  3–4 independent experiments with
triplicate samples within each experiment.
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FIG. 3. NO
● levels in BREC (A) and BRP (B) after treatment with Ang
II and Cand for 24 h. A: Treatment of BREC with 100 nmol/l Ang II had
no effect on NO
● levels. In BREC treated with Ang IICand (1 mol/l),
NO
● levels were reduced below both control and Ang II treated cells.
*P < 0.01 versus control, †P < 0.03 versus Ang II. B: Treatment of BRP
with 100 nmol/l Ang II signiﬁcantly increased NO
● levels. In BRP
treated with Ang IICand, NO
● levels were reduced to control levels.
*P < 0.05 versus control, †P < 0.05 versus Ang II. BRP were analyzed
by one-way ANOVA, followed by Bonferroni post hoc tests. BREC were
analyzed by Kruskal-Wallis tests followed by Mann-Whitney U tests.
Values are the means of 3 and 7 independent experiments (BRP and
BREC, respectively) with triplicate samples within each experiment.
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with nondiabetic controls, and candesartan reduced reti-
nal iNOS mRNA levels to below the level of nondiabetic
controls (Fig. 6).
Retinal pathology in diabetic Ren-2 rats is associated
with a reduction in retinal GLO-I. In Ren-2 rats, the
retinal pathology that occurred at 4 and 20 weeks of
diabetes was accompanied by modulations in GLO-I func-
tion. A decrease in retinal GLO-I activity was observed at
4 weeks of diabetes, although changes in mRNA levels
were not detected (Fig. 7 and supplementary Fig. 2,
available in the online appendix, respectively). However,
after 20 weeks of diabetes, retinal GLO-I mRNA was
decreased (Fig. 7). Candesartan increased GLO-I expres-
sion in the retina of diabetic Ren-2 rats, which is consistent
with our ﬁndings in BREC and BRP. To determine whether
the reduction in retinal GLO-I in diabetic Ren-2 rats is
related to the overexpression of the RAS in these animals,
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tive micrographs from Ren-2 rats after 20 weeks of diabetes. Retina
stained with Periodic-acid Schiff’s reagent. Scale bar  20 m. Nondi-
abetic (A), diabetic (B), and diabeticCand (5 mg/kg/day) (C). In
diabetic Ren-2 rats, acellular capillaries were increased in the mid and
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diabeticCand. N  8 animals/group. Data were analyzed by one-way
ANOVA, followed by Bonferroni post hoc tests. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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Sprague-Dawley rats with a suppressed RAS (Fig. 7). The
expression of GLO-I in retina from nondiabetic Sprague-
Dawley rats was unchanged with diabetes. We then inves-
tigated whether GLO-I dysregulation by the RAS increased
MGO-derived AGEs. After 4 weeks of diabetes in Ren-2
rats, MGO-AGE levels in retina were increased. In diabetic
Ren-2 rats, candesartan tended to reduce the increase in
retinal MGO-AGE, but this was not signiﬁcant (Fig. 7). The
speciﬁc MGO-AGE, argpyrimidine, was also measured in
retina and was unchanged with diabetes in the Ren-2 rat;
however, candesartan did reduce the levels of retinal argpyri-
midine compared with controls (Fig. 7). After 20 weeks of
diabetes, both plasma MGO-AGEs and total AGEs were
elevated in diabetes and signiﬁcantly reduced with candesar-
tan (Fig. 7). Retinal NO
● was signiﬁcantly suppressed in the
diabetic Ren-2 rats treated with candesartan compared with
both diabetic and nondiabetic controls (Fig. 7).
Body weight, blood glucose, and systolic blood pres-
sure. The results are found in the online appendix in Table S2.
DISCUSSION
The present study provides novel evidence that GLO-I, an
enzyme critical for retinal vascular cell survival (12), is
downregulated by Ang II in the retina. Our ﬁndings are
supported by evidence that the AT1-RB, candesartan,
improves acellular capillary formation and inﬂammation in
diabetic retinopathy with a concomitant restoration of
retinal GLO-I expression and a reduction of MGO-AGEs
and, in particular, the speciﬁc MGO-AGE argpyrimidine.
These ﬁndings broaden the known actions of Ang II in the
AGE pathway to include not only extracellular AGE-
related events such as RAGE-mediated cellular apoptosis
(24,29,30) but also the intracellular formation of MGO-
AGEs. In terms of the mechanism by which retinal GLO-I
is regulated, our previous study in retinal pericytes indi-
cated a role for NO
● (12). We now extend this ﬁnding to
report that, in retinal vascular cells, candesartan reduces
NO
● levels, which is accompanied by the restoration of
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FIG. 6. ICAM-1 (A), VEGF (B), TNF- (C), and iNOS (D) mRNA levels
in retina of Ren-2 rats after 4 weeks of diabetes. Retinal ICAM-1,
VEGF, TNF-, and iNOS mRNA levels are increased in diabetic Ren-2
rats compared with nondiabetic control. In diabetic Ren-2 rats, Cand
reduced both retinal ICAM-1 (A) and VEGF mRNA (B) to the level of
nondiabetic controls, with TNF- (C) and iNOS mRNA (D) decreasing
to below control levels. For panels A, B, and D, data were analyzed by
one-way ANOVA, followed by Bonferroni post hoc tests. *P < 0.05
versus nondiabetic control. †P < 0.05 versus diabetic control. For
panel C, data were analyzed by Kruskal-Wallis tests followed by
Mann-Whitney U tests. *P < 0.02 versus nondiabetic control. †P <
0.0001 versus diabetic control. N  8–13 animals/group. Values are
mean  SEM.
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FIG. 7. GLO-I activity and mRNA, and MGO-AGE levels in diabetic
Ren-2 rats. In Ren-2 rats after 4 weeks of diabetes, retinal GLO-I
activity (A) is reduced compared with nondiabetic control and tends to
be restored with Cand, although this is not signiﬁcant (*P < 0.03 vs.
nondiabetic Ren-2 control). In Ren-2 rats after 20 weeks of diabetes,
retinal GLO-I mRNA (B) is clearly reduced compared with nondiabetic
control and is restored to control levels with Cand (*P < 0.005 vs.
nondiabetic Ren-2 control, †P < 0.05 vs. diabetic Ren-2 control). In
comparison, in Sprague-Dawley (SD) rats (B), no changes in retinal
GLO-I mRNA are observed with 20 weeks of diabetes. In Ren-2 rats
after 4 weeks of diabetes, the reduction in retinal GLO-I activity (A)i s
accompanied by an increase in the levels of retinal MGO-AGE (C),
(*P < 0.01 vs. nondiabetic Ren-2 control). In diabetic Ren-2 rats, Cand
tends to decrease the levels of retinal MGO-AGE, but this is not
signiﬁcant. In diabetic Ren-2 rats at 4 weeks, the levels in retina of the
speciﬁc MGO-AGE, argpyrimidine (D), and NO
● levels (E) are un-
changed compared with nondiabetic controls; however, Cand reduced
retinal argpyrimidine (*P < 0.05 vs. nondiabetic Ren-2 control, †P <
0.01 vs. diabetic Ren-2 control) and NO
● levels (*P < 0.05 vs. nondia-
betic Ren-2 control. †P < 0.01 vs. diabetic Ren-2 control). F: Plasma
MGO-AGEs (black bars) are increased in Ren-2 rats after 20 weeks of
diabetes compared with nondiabetic controls and are reduced with
Cand to nondiabetic levels (*P < 0.05 vs. nondiabetic Ren-2 control;
†P < 0.05 vs. diabetic Ren-2 control). Other AGEs (non-MGO AGEs,
white bars) and total AGEs (MGO-AGE  other AGEs, black  white
bars) were increased in Ren-2 rats after 20 weeks of diabetes and
reduced with Cand to nondiabetic control levels (‡P < 0.005 versus
“other AGE” nondiabetic Ren-2 control; §P < 0.04 versus “other AGE”
diabetic Ren-2 control; #P < 0.02 versus “total AGE” nondiabetic
Ren-2 control; **P < 0.02 versus “total AGE” diabetic Ren-2 control).
N  5–8 animals/group. Values are mean  SEM. Data in panels C and
D were analyzed by one-way ANOVA, followed by Bonferroni post hoc
tests. All other datasets in this ﬁgure were analyzed by Kruskal-Wallis
tests, followed by Mann-Whitney U tests.
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tion about how Ang II interacts with the AGE pathway and
the cellular mechanisms by which candesartan exerts its
potent protective effects in diabetic retinopathy (Fig. 8).
At 20 weeks of diabetes, we observed increased acellu-
lar capillary formation in the mid and peripheral retina of
the Ren-2 rat, which is consistent with our previous
studies in the Ren-2 rat (13) and observed in diabetic
patients (31). Acellular capillary formation is a pathology
that occurs in retinal microvessels after the apoptosis of
both endothelial cells and pericytes (32). These events
may result in areas of retinal nonperfusion, which are
viewed to lead to the upregulation of angiogenic growth
factors such as VEGF with subsequent pathological angio-
genesis. The mechanisms responsible for retinal vascular
cell apoptosis are not fully deﬁned; however, previous
studies by our group indicate that GLO-I is necessary for
the survival of human retinal pericytes (12). The present
study builds on this information by identifying in retinal
vascular cells that Ang II is a novel, negative regulator of
GLO-I activity and expression and inducer of cellular
apoptosis. Supporting an interaction between Ang II and
GLO-I is our ﬁnding that, in diabetic Ren-2 rats with an
enhanced extrarenal RAS in tissues including the eye (15),
retinal GLO-I expression is reduced with a concomitant
increase in acellular capillaries. It is noteworthy that, in
age-matched diabetic Sprague-Dawley rats, retinal GLO-I
is not reduced and these animals do not develop acellular
capillaries (13). We acknowledge that GLO-I activity was
not measured in long-term diabetes when acellular capil-
laries appear; nevertheless, GLO-I activity was reduced in
the early stages of diabetic retinopathy when inﬂammation
is maximal. The ability of candesartan to restore retinal
GLO-I and attenuate retinal vasculopathy including inﬂam-
mation, which is viewed to contribute to diabetic retinop-
athy (33), may be important when considering the
underlying mechanisms by which Ang II blockers such as
candesartan provide retinoprotection.
Although the glyoxalase system is a critical regulator of
the AGE pathway, it is the formation of MGO-AGEs that
are implicated in cellular damage. To date, the majority of
studies in this area have focused on the contribution of
AGEs via RAGE to AGE-mediated pathology, including in
diabetic retinopathy (34). However, AGEs may not be the
primary RAGE ligands in vivo, given that proteins must be
heavily glycated before they can bind to RAGE, and this
extensive glycation may not occur to a major extent in
vivo (35). There are limited reports detailing the contribu-
tion of intracellular AGEs to pathology, although there is
increasing evidence to support this possibility (36,37).
Another dimension to the RAGE paradigm is the recent
ﬁnding that GLO-I can control the expression of RAGE and
its ligands by modulating the levels of MGO (38), consis-
tent with the view that intracellular glycation can control
RAGE expression. The inﬂuence of the RAS on AGE
formation has been established in the diabetic nephropa-
thy (20–23), with in general a focus on RAGE-mediated
signaling. This is true also for the limited studies in
diabetic retinopathy, where Ang II mediates increases in
RAGE and AGE-induced apoptosis of retinal pericytes
(24,29,30). In the present study, an evaluation of intracel-
lular MGO-AGE formation, as detected by ELISA using an
antibody raised against a heterogeneous mixture of MGO-
AGEs, revealed an increase in retina from diabetic Ren-2
rats. A speciﬁc MGO-AGE, argpyrimidine, formed on reac-
tion of MGO with arginine residues, was also examined,
given the known preferential modiﬁcation of arginine over
lysine (39) and the previous detection of this speciﬁc
moiety in the diabetic kidney (39,40). However, despite an
elevation in retinal MGO-AGEs in diabetic Ren-2 rats,
argpyrimidine was not increased, a ﬁnding which may be
explained by its presence in lower quantities relative to
other MGO-AGEs (41). Further evidence that Ang II inﬂu-
ences retinal MGO-AGEs arises from our ﬁnding that
candesartan, which restored GLO-I in diabetic Ren-2 ret-
ina, also reduced retinal MGO-AGEs and argpyrimidine
levels. These results are consistent with a previous study,
which reported that candesartan reduced immunolabeling
of the AGE pentosidine in the retina of diabetic rats,
although in that study pentosidine levels were not specif-
ically quantitated (42). Consistent with candesartan’s re-
duction of retinal MGO-AGEs, candesartan lowered
plasma MGO-AGE, and it is noteworthy that the majority
of AGEs detected in plasma using our assay were MGO-
derived. Overall, our ﬁndings establish a mechanism for
the observed regulation of AGEs by the RAS in diabetic
retinopathy that may be indeed relevant to other diabetic
complications (20–23).
A possible candidate for Ang II’s downregulation of
GLO-I in the retina is via an increase in NO
●. This postulate
is based on our previous studies in human retinal peri-
cytes, which indicated that GLO-I is regulated at the
transcriptional level by NO
● (12). Furthermore, there is
considerable evidence that Ang II stimulates NO
● production,
which leads to vascular pathology (43), including retinal
inﬂammation and breakdown of the blood–retinal barrier
(44,45). In the present study, although Ang II reduced
GLO-I activity and expression in both cultured retinal
endothelial cells and pericytes, it only increased NO
●
levels in retinal pericytes. The reasons for Ang II not
stimulating NO
● in retinal endothelial cells is not clear;
however, our data would indicate that Ang II via the AT1-R
inﬂuences NO
● production in retinal endothelial cells, with
candesartan reducing NO
● levels in both cell populations.
Similarly, in Ren-2 retina, NO
● levels were not signiﬁcantly
elevated with diabetes; however, candesartan reduced
NO
● levels below nondiabetic control, supporting the idea
that in retina Ang II inﬂuences NO
● production via the
AT1-R. A consideration when interpreting our results is
that physiological levels of NO
● are required for normal
tissue function and can inhibit leukocyte adhesion (46)
and mediate vasorelaxation (47). Our ﬁnding that cande-
sartan reduced retinal iNOS and NO
● below control levels
may indicate that further studies are required to determine
whether lower doses of AT1-RB can maintain NO
● at
physiological levels within the retina with a concomitant
reduction in retinal pathology and restoration of GLO-I. In
terms of a pathological role for the NO
● system in diabetic
retinopathy, our ﬁndings are consistent with previous
studies where iNOS is implicated as a major contributor to
NO
Ang II AGEs
AT1-RB
restores GLO-I and
prevents retinal
vasculopathy
Retinal
Vascular injury
GLO-I X
FIG. 8. Proposed mechanism by which Ang II downregulates GLO-I in
retinal vascular cells, leading to the generation of AGEs and vascular
injury. The AT1-RB, Cand, is able to prevent diabetic retinal vascular
injury by reducing nitric oxide and restoring GLO-I levels.
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● levels in diabetic retinopathy (48,49)
and reports that tissue iNOS can be reduced with cande-
sartan (22).
A possible limitation of the present study is that the
effectiveness of candesartan on diabetic retinopathy in the
Ren-2 rat could be due to a reduction of the hypertension
of this animal rather than inhibition of the growth factor
effects of angiotensin II. However, in our previous studies,
a comparison of age- and blood pressure-matched diabetic
spontaneously hypertensive rats to diabetic Ren-2 rats
revealed that the former did not develop as severe diabetic
retinopathy, suggesting that the overexpression of the RAS
in the Ren-2 rat was largely responsible for the develop-
ment of diabetic retinopathy in this model (15). Further-
more, in diabetic Ren-2 rats, the -blocker, atenolol, and
the AT1-RB, valsartan, both produced similar reductions in
systolic blood pressure; however, only valsartan attenu-
ated retinal acellular capillary formation and the decline in
retinal function (13,14). Nonetheless, whether hyperten-
sion per se inﬂuences retinal GLO-I activity and expression
in diabetes is to our knowledge unknown and warrants
investigation in future studies.
In conclusion, the results from the current study are
timely, given the positive ﬁndings from recent clinical
trials, which indicate that AT1-RB and angiotensin con-
verting enzyme inhibition confer protective effects on the
retinal vasculature in diabetic retinopathy (18,19,50). Our
data suggest that GLO-I could be a key enzyme that
bridges the RAS and AGE pathways, thereby contributing
to the development of diabetic retinopathy (Fig. 8). These
ﬁndings enhance our understanding of how RAS blockers
such as candesartan act at the molecular level to confer
retinal vascular protection in disorders such as diabetes.
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